Medicare Rx "Non-Interference" Provision Protects Patients, PhRMA CEO Maintains
This article was originally published in The Pink Sheet Daily
Executive Summary
Language in the Medicare prescription drug law that prohibits HHS from "interfering" in drug price negotiations will ensure that patients have more therapeutic options, Pharmaceutical Research & Manufacturers of America CEO Alan Holmer maintained during the trade group's annual meeting in Palm Beach, Fla. April 2.